Translate Bio (NASDAQ:TBIO) had their “buy” rating restated by Research analysts at Svb Leerink in a research note issued to investors on Tuesday, TipRanks reports. They presently have a $20.00 target price on the stock. Svb Leerink’s target price points to a potential upside of 87.44% from the company’s current price.
Several other brokerages have also issued reports on TBIO. Roth Capital started coverage on shares of Translate Bio in a research note on Tuesday, June 18th. They set a “buy” rating and a $25.00 price target for the company. Jefferies Financial Group began coverage on shares of Translate Bio in a report on Monday, July 22nd. They issued a “buy” rating and a $20.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Translate Bio in a report on Thursday, August 1st. Citigroup set a $17.00 price objective on shares of Translate Bio and gave the stock a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research raised shares of Translate Bio from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $21.60.
Shares of TBIO stock traded up $0.26 during trading hours on Tuesday, hitting $10.67. 6,885 shares of the company were exchanged, compared to its average volume of 304,121. The firm has a fifty day simple moving average of $8.71 and a 200 day simple moving average of $9.82. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 1.15. Translate Bio has a 52-week low of $4.81 and a 52-week high of $14.34. The stock has a market capitalization of $500.41 million, a price-to-earnings ratio of -3.00 and a beta of 0.90.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TBIO. Baupost Group LLC MA boosted its holdings in Translate Bio by 36.2% in the 2nd quarter. Baupost Group LLC MA now owns 8,844,239 shares of the company’s stock worth $109,372,000 after buying an additional 2,352,941 shares during the period. Vanguard Group Inc. boosted its holdings in Translate Bio by 80.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,524,907 shares of the company’s stock valued at $19,259,000 after purchasing an additional 680,330 shares during the period. BlackRock Inc. boosted its holdings in Translate Bio by 28.0% in the 2nd quarter. BlackRock Inc. now owns 2,515,392 shares of the company’s stock valued at $31,769,000 after purchasing an additional 549,817 shares during the period. Highbridge Capital Management LLC bought a new position in Translate Bio in the 2nd quarter valued at $3,867,000. Finally, Monashee Investment Management LLC bought a new position in Translate Bio in the 2nd quarter valued at $3,789,000. 72.68% of the stock is owned by institutional investors.
About Translate Bio
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.